Flowcount b fc 3100 gamma detector

All solvents were purchased from Sigma-Aldrich and used without further purification. The amino(oxy)-peptide was purchased from Biomatik (Ontario, Canada) in acetate salt at a purity of >98%. [¹⁸F]Fluoride was produced onsite via the ¹⁸O(p, n)¹⁸F nuclear reaction by 16.4 MeV proton bombardment of enriched [¹⁸O]H₂O using a GE PETtrace cyclotron (Bucks, UK). Analytical HPLC was performed using a Shimadzu (Milton Keynes, UK) Prominence system (LC-20AB solvent delivery system, SPD-20A dual wavelength absorbance detector) controlled by Laura 3 software (LabLogic, Sheffield, UK), Laura 3 software via a CBM-20A controller. HPLC eluate was measured for radioactivity using a Bioscan (Oxford, UK) Flowcount B-FC 3100 gamma detector. All pre-clinical PET scans were carried out using a Siemens (Oxford, UK) Inveon® PET-CT scanner. MALDI-MS was carried out using AXIMA performance MALDI-TOF MS (Shimadzu, UK). Mass spectra were acquired using a Waters SQD2 (Waters, UK) and ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer (Bruker, US) operated with TOPSPIN NMR software (version 2.0).

All solvents were purchased from Sigma‐Aldrich (Gillingham, Dorset, UK) and used without further purification. rhIL‐1RA (100 mg/ml), anakinra (Kineret) was provided by Amgen (Thousand Oaks, CA, USA) in a formulated solution containing 100‐mg anakinra, 1.29‐mg sodium citrate, 5.48‐mg sodium chloride, 0.12‐mg disodium EDTA and 0.70‐mg polysorbate 80 in 1‐ml water.
[¹⁸F]Fluoride was produced onsite via the ¹⁸O(p, n)¹⁸F nuclear reaction by 16.4‐MeV proton bombardment of enriched [¹⁸O]H₂O using a GE (Amersham, Bucks, UK) PETtrace cyclotron.
Analytical HPLC was performed using a Shimadzu (Milton Keynes, UK) Prominence system (LC‐20AB solvent delivery system, SPD‐20A dual wavelength absorbance detector) controlled by LabLogic (Sheffield, UK) Laura 3 software via a CBM‐20A controller. HPLC eluate was measured for radioactivity using a Bioscan (Oxford, UK) Flowcount B‐FC 3100 gamma detector. All pre‐clinical PET scans were carried out using a Siemens (Oxford, UK) Inveon® PET‐CT scanner.

All solvents were purchased from Sigma‐Aldrich and used without further purification. (Aoa)F9 was purchased from Biomatik (Ontario, Canada) in trifluoroacetic acid (TFA) salt, purity >98%. FITC‐F9 was purchased from Biomatik as a TFA salt (purity >98%) and converted into the HCl salt of the peptide. [¹⁸F]Fluoride was produced onsite via the ¹⁸O(p, n)¹⁸F nuclear reaction by 16.4 MeV proton bombardment of enriched [¹⁸O]H₂O using a GE PETtrace cyclotron (GE Healthcare, Sweden). Analytical HPLC was performed using a Shimadzu (Milton Keynes, UK) Prominence system (LC‐20AB solvent delivery system, SPD‐20A dual wavelength absorbance detector) controlled by LabLogic (Sheffield, UK), Laura 3 software via a CBM‐20A controller. HPLC eluate was measured for radioactivity using a Bioscan (Oxford, UK) Flow‐count B‐FC 3100 gamma detector. All preclinical PET scans were carried out using a Siemens (Oxford, UK) Inveon® PET‐CT scanner. Fluorescence in vivo imaging was carried out using a Biospace Lab Photon Imager Optima (Nesles‐la‐Valee, France) controlled by Biospace Lab Photo Acquisition software v3.4 and images analysed using Biospace Lab M3 Vision software.